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Abstract
Summary Increased fracture risk in patients with Ehlers-Danlos syndromes has been reported, but the reasons for it are incom-
pletely understood. We aimed to investigate possible determinants of this increased risk and found that hEDS/HSD patients
present with a cortical bone size deficit compared with control subjects, possibly related to lower mechanical loading.
Introduction The Ehlers-Danlos syndromes (EDS) comprise a group of heritable connective tissue disorders caused by defects in
the biosynthesis, secretion, and/or organization of fibrillar collagens which might impair bone strength. Our aim was to compare
fracture prevalence, volumetric and areal bone mineral density (BMD), bone geometry, muscle size and the muscle-bone
interaction, body composition and longitudinal changes therein between patients with hypermobile EDS (hEDS) or hypermo-
bility spectrum disorder (HSD), and healthy control subjects.
Methods Cross-sectional data comprised 39 female hEDS/HSD patients (age 41 ± 11 years) and 43 age-matched controls. After
8 years, 27 hEDS/HSD and 17 control subjects were re-evaluated. Tibial trabecular and cortical volumetric BMD, bone mineral
content (BMC), cortical bone geometry, and lower leg muscle cross-sectional area (CSA) were measured using pQCT. Body
composition, areal BMD, and BMC were determined by DXA.
Results At baseline, patients with hEDS/HSD presented with a smaller cortical bone area, smaller cortical thickness and muscle
CSA, and a higher fracture prevalence than control subjects (all p < 0.05). No differences in areal or volumetric BMDwere found.
Longitudinally, muscle CSA decreased in both groups and muscle density decreased in the hEDS/HSD group (p < 0.001)
whereas all bone parameters remained unchanged.
Conclusion hEDS/HSD patients have a cortical bone size deficit compared with controls, possibly contributing to their increased
fracture risk. They presented with decreased muscle CSA but normal bone/muscle area ratio, suggesting that this bone size deficit is
likely secondary to decreased mechanical loading. Further, there were no arguments for accelerated bone loss in hEDS/HSD subjects.
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Introduction
The Ehlers-Danlos syndromes (EDS) comprise a group of
clinically and genetically heterogeneous heritable connective
t i s sue d i sorde rs tha t a re charac te r i zed by skin
hyperextensibility and fragility, joint hypermobility, and gen-
eralized connective tissue fragility. The Villefranche nosology
has been the standard for classifying EDS during the last two
decades. However, over the years, distinct EDS subtypes have
been delineated, and different defects were identified in an
array of genes with diverse biological functions linked to col-
lagen biosynthesis, assembly, and organization [1]. The latest
EDS classification now recognizes 13 distinct EDS subtypes
caused by defects in 19 different genes and provides a
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regrouping based on the underlying genetic and pathogenic
mechanisms [2]. However, the genetic basis of hypermobile
EDS (hEDS), the most common subtype of EDS, is still large-
ly unknown. Consequently, hEDS remains a clinical diagnosis
based on generalized joint hypermobility, leading to musculo-
skeletal complications such as musculoskeletal pain, recurrent
joint (sub) luxations or joint instability, and multiple signs of
extra-articular soft tissue fragility [2]. Patients who do not
meet the criteria for hEDS in the new EDS nosology are la-
beled as hypermobility spectrum disorder (HSD), which is
likely a multifactorial disorder [3].
As collagen is a major component of the bone matrix, bone
strength might be impaired in hEDS patients [4–6]. Until now,
however, literature on this topic is limited. A few studies have
shown a higher fracture prevalence in (h)EDS patients [7–9].
Some studies showed a lower areal bone mineral density
(aBMD) in hEDS patients (according to the Villefranche
criteria) compared with controls [7, 10–12], whereas in pa-
tients with joint hypermobility syndrome contradictory results
were reported [13–15]. Furthermore, bone mass and size ac-
crual which should lead to peak bone mass at adult age are
processes which are largely dependent on mechanical strain
caused by skeletal muscle contraction mediated through ten-
dons. Altered muscle-tendon properties [16], reduced muscle
strength [16, 17], pain and fatigue, and recurrent injuries likely
play a role in the decreased physical activity observed in pa-
tients with hEDS [18] which could indirectly contribute to
unfavorable (geometric) bone properties, a lesser peak bone
mass and more rapid bone loss with aging [16–19].
To this date, however, evaluation of bone properties in
patients with EDS was performed using dual-energy x-ray
absorptiometry (DXA) and ultrasound, limiting our knowl-
edge on bone geometric characteristics, bone/muscle relation-
ships, and possible differences in volumetric BMD (vBMD)
in different bone compartments. Therefore, this study evalu-
ated, in addition to DXA measurements, cortical and trabecu-
lar bone geometry, vBMD, muscle size, and density using
peripheral quantitative computed tomography (pQCT) in pa-
tients with hEDS or HSD as compared with age- and sex-
matched controls. In addition, some of the participants were
re-evaluated after 8 years to investigate differences in bone
loss and changes in bone geometry and muscle characteristics
over time.
Materials and methods
Study design and subjects
At baseline (2009), 43 women with the hypermobility type of
EDS diagnosed according to the Villefranche criteria [20]
were recruited at the Centre for Medical Genetics at Ghent
University Hospital. Exclusion criteria for both groups were
musculoskeletal injury at the lower extremity or knee surgery
in the past 2 years, and use of drugs affecting bone strength or
metabolism (tamoxifen, letrozole, raloxifen, testosterone,
alendronic acid, risedronic acid, strontium ranelate, zoledronic
acid, calcitonin, and teriparatide). Two patients were excluded
due to the former use of calcitonin, and 2 patients were ex-
cluded due to the current use of alendronic acid. In addition,
43 age-matched control women were included. Additional
exclusion criteria for control subjects were a Beighton score
of > 4/9, current lower extremity pain, and participation in
competitive sports. Eight years later (2017), all patients and
controls were contacted to participate in a follow-up evalua-
tion. Twenty-seven EDS patients (72.9%) and 17 healthy con-
trols (39.5%) consented to be reassessed. Reasons for
dropping out were no up-to-date contact details, no time for
participation because of work, or no more interest to partici-
pate in the study. It is important to note that the EDS nosology
was revised in 2017, shortly before the follow-up measure-
ment. The 2017 EDS nosology redefines “hypermobile EDS”
by using more stringent clinical criteria compared with the
previous Villefranche nosology. Consequently, 20 patients
previously diagnosed as having the hypermobility type of
EDS (then abbreviated as “EDS-HT”), are currently
reclassified as having hypermobility spectrum disorder (ab-
breviated as “HSD”), while 10 patients retained the diagnosis
of hypermobile EDS (now abbreviated as “hEDS”).
As no differences in bone characteristics between subjects
with hEDS and HSD were found at follow-up (data not
shown, all p > 0.11), analyses were done on the whole group
of patients, referred to as “hEDS/HSD” in this paper. All par-
ticipants gave written informed consent to participate in the
study, which was approved by the Ethical Review Board of
the Ghent University Hospital and conducted according to the
principles of the Declaration of Helsinki.
Anthropometry, muscle size, and body composition
Body weight was measured to the nearest 0.1 kg using a cal-
ibrated SECA balance measuring scale (SECA, Deutschland,
Hamburg, Germany) in indoor clothing without shoes.
Standing height was measured using a wall-mounted
Harpenden stadiometer (Holtain, Crymuch, UK). Body mass
index (BMI) (kg/m2) was calculated. Whole body composi-
tion was measured using DXA with a Hologic QDR-
Discovery device (software version 2.3.1; Hologic, Bedford,
MA, USA). The coefficient of variation was < 1% as calculat-
ed for whole-body calibration phantoms. Reproducibility of
pQCT measurements in human subjects was evaluated in 10
patients with a CV < 2.6% for multiple measurements.
Measurements include fat mass (whole body minus head)
and lean mass (whole body minus head) (kg). Peripheral
quantified–computed tomography (pQCT) was used for as-
sessment of the total cross-sectional area (CSA, mm2) muscle
Osteoporos Int
CSA (mm2), muscle density (mg/cm3) and fat CSA (mm2) at
the dominant lower leg (66% of bone length from the distal
end). Bone/muscle area ratio was calculated. The device used
was a XCT-2000 (Stratec Medizintechnik, Pforzheim,
Germany) as described below, with CV for the calibration
phantom < 1% as calculated from daily measurements and <
2.6% in human subjects.
Bone mineral density, geometry, and estimates
of bone strength
Bone mineral content (BMC, mg), aBMD (mg/cm2), and bone
area (cm2) were measured at the whole body (whole body minus
head) using DXA. The Z-score was calculated for the whole
body. Volumetric BMD, geometric bone parameters, and esti-
mates of bone strength were determined at the dominant lower
leg (tibial shaft, at 4% and 66% of bone length from distal) using
pQCT. Single tomographic slices of 2.0-mm thickness were tak-
en at a voxel size of 0.8 mm and a scan speed of 20 mm/s.
Trabecular bone area (mm2), trabecular bone content (mg/mm),
and trabecular bone density (mg/cm3) were measured at the 4%-
site (see Fig. 1). Cortical bone content (mg/mm), cortical bone
area (mm), cortical bone density (mg/cm3) (vBMD), cortical
thickness (mm), periosteal circumference (mm), endosteal cir-
cumference (mm), and polar stress strain index (SSIp,mm3)were
measured at the 66%-site (see Fig. 1). Endosteal/periosteal cir-
cumference ratio at the 66%-site was calculated. Imaging and the
calculation of numerical values were performed using the man-
ufacturer’s software package (version 5.4).
Physical activity and fracture prevalence
The Baecke questionnaire was used for assessing physical
activity (PA). This questionnaire quantifies work, leisure,
and sports activities using a 5-point scale ranging from “nev-
er” to “always”. The summation of these three indicates the
level of habitual physical activity. Higher scores indicate a
higher level of habitual physical activity [21]. Fracture
Fig. 1 Schematic overview of
measurements performed at the
66% region (shaft, used for
evaluating cortical bone
parameters) and 4% region (distal
region, used for evaluating
trabecular bone parameters) of the
lower leg
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prevalence was evaluated at baseline using a self-developed
questionnaire. Fractures of the skull, hip, axial skeleton, tibia,
fibula, radius, and ulna were considered as major fractures.
Fractures of digits, toes, metacarpals, carpals, metatarsals, tar-
sal, clavicula, nose, and rib were considered as minor fractures.
Statistical analysis
All variables were subjected to testing for normality of
distribution and are presented as estimated means with
95% confidence intervals. Age is shown as mean ±
standard deviation. Height and weight were compared
cross-sectionally and longitudinally using linear mixed
effect modeling to evaluate differences at baseline after
correction for age. Cross-sectional comparison between
groups for all parameters, except age, height, and
weight, was performed using linear mixed-effects
modeling to evaluate differences at baseline after correc-
tion for confounding factors (age, weight, height, and
physical activity). The repeated covariance type was
compound symmetry. Age, time, group, height, weight,
and physical activity were used as fixed factors. For all
parameters except age, linear mixed-effects modeling
were used for longitudinal analyses. The repeated co-
variance type was compound symmetry, and age, time,
group, physical activity, weight, and height (if applica-
ble) were used as fixed factors. Test results were con-
sidered statistically significant at p values < 0.05. IBM
SPSS statistics (version 25, Chicago, IL, USA) was
used for all statistical analysis. Fracture prevalence was
dichotomized, after which a Fisher’s exact test was per-
formed for the evaluation of difference between the two
study groups.
Results
Anthropometry, muscle size, and body composition
Table 1 shows the subjects’ characteristics at baseline and
follow-up. At baseline, 7 patients were in menopause, and 3
patients were in menopause transition, whereas 6 control sub-
jects were in menopause and 3 were in transition. The
hEDS/HSD group and control group did not differ in age
and weight. However, patients with hEDS/HSD were
somewhat shorter and had a higher BMI (all p < 0.05). Both
groups also differed in body composition with patients with
hEDS/HSD presenting with less lean mass (p = 0.017) and
more fat mass than controls, even after correcting for height,
weight, and PA level (p = 0.017). At the lower leg, no signif-
icant differences were found in muscle density, bone/muscle
area ratio, and fat CSA, but hEDS/HSD subjects had a small-
er muscle CSA compared with controls (p = 0.022 after cor-
rection for height, weight, and PA, see Fig. 2 for represen-
tative pQCT-images of both groups). At follow-up, most of
these between-group findings were similar except for the
Table 1 Anthropometry, muscle size and body composition at baseline and follow-up
Baseline Follow-up
hEDS/HSD-group (n = 39) Control group (n = 43) hEDS/HSD-group (n = 27) Control group (n = 17)
Age (years) 41 ± 11 41 ± 11 48 ± 12 49 ± 12
Height (m) 1.64 (1.62, 1.66)a 1.67 (1.65, 1.69) 1.65 (1.62, 1.67)b 1.68 (1.6, 1.70)
Weight (kg) 73.8 (68.8, 78.8) 67.8 (63.0, 72.5) 77.1 (71.6, 82.7) 71.0 (65.0, 77.0)
BMI (kg/m2) 27.5 (25.7, 29.2)a 24.3 (22.6, 25.9) 28.5 (26.5, 30.4)b 25.1 (23.0, 27.3)
Lean mass (kg) 41.21 (40.10, 42.33)a 43.17 (42.10, 44.25) 42.28 (40.80, 43.75) 43.53 (41.87, 45.19)
Fat mass (kg) 25.13 (24.10, 26.17)a 23.33 (22.32, 24.33) 25.59 (24.29, 26.90)b 23.44 (22.02, 24.86)
Muscle density (mg/cm3) 76.65 (75.93, 77.37)c, e 76.14 (75.27, 77.02)e 75.02 (74.24, 75.80)b 76.99 (76.08, 77.90)
Muscle CSA (cm2) 64.10 (60.86, 67.35)a, c 70.18 (66.23, 74.13)d 55.81 (52.25, 59.36)b 62.05 (57.39, 66.72)
Fat CSA (cm2) 38.90 (35.19, 42.61) 34.47 (29.93, 39.01) 39.30 (35.35, 43.26)b 32.24 (27.32, 37.16)
BMR (%) 4.5 (4.3, 4.8)c 4.3 (4.0, 4.5)d 4.9 (4.6, 5.3) 4.7 (4.3, 5.1)
a p value for estimated mean baseline difference between EDS and CON < 0.05
b p value for estimated mean difference at V2 between EDS and CON < 0.05
c p value for estimated mean difference between V1 and V2 for EDS < 0.05
d p value for estimated mean difference between V1 and V2 for CON < 0.05
e p value for interaction time*group < 0.05
Age is presented as the mean (± stdev). Values are the estimated means (95% confidence interval). hEDS/HSD hypermobile EDS/hypermobility
spectrum disorder; BMI body mass index; CSA cross-sectional area; BMR bone/muscle area ratio
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difference in lean mass which was no longer significant. In
addition, patients with hEDS/HSD had larger fat CSA at
follow-up (p = 0.028). Further, longitudinal analyses
showed similar changes in muscle CSA and BMR in both
groups, and a decrease in muscle density in the hEDS/HSD
group only (p < 0.001) leading to a significant between-
group difference therein at follow-up (p = 0.02). Other mea-
sures of body composition did not change over time in either
group.
Physical activity and fracture prevalence
The physical activity score at baseline differed significantly
between patients and controls, with lower scores for the
hEDS/HSD population (p < 0.001). During follow-up, no
change in PA level was observed in either group. The number
of subjects at baseline with major fractures was significantly
higher in hEDS/HSD (18 out of 42) compared with controls (6
out of 42) (p = 0.004). In contrast, no significant differences
for minor fractures were found.
Bone mineral density, geometry, and estimates
of bone strength
Table 2 shows DXA-derived bone parameters at baseline and
follow-up. No difference in whole body Z-score was observed
between the hEDS/HSD and control group, with Z-scores
within the normal range for both groups. In addition, there
were no significant differences in other DXA-derived bone
parameters, either at the whole body or the lumbar spine.
Longitudinal analyses did not show changes over time in bone
area, BMC, or aBMD at either site in any group (Table 2).
Fig. 2 Representative pQCT
images (at 66% region of tibial
shaft) in hEDS/HSD patients
(left) and for controls (right)
Table 2 DXA-derived parameters at baseline and follow-up
Baseline Follow-up
hEDS/HSD-group (n = 39) Control group (n = 43) hEDS/HSD-group (n = 27) Control group (n = 17)
Z-score whole body 0.15 (− 0.17, 0.47) 0.37 (0.57, 0.68) 0.02 (− 0.35, 0.39) 0.18 (− 0.20, 0.57)
Whole body BMC (g) 1610.08 (1549.33, 1670.83) 1660.31 (1601.65, 1718,97) 1567.94 (1496.35, 1639.53) 1596.46 (1520.45, 1672.47)
Whole body bone area (cm2) 1819.48 (1785.41, 1853,55) 1831.13 (1798.23, 1864.02) 1808.93 (1766.47, 1851.38) 1819.64 (1772.29, 1866.99)
Whole body BMD (g/cm2) 0.878 (0.852, 0.903) 0.903 (0.879, 0.927) 0.853 (0.820, 0.887) b 0.921 (0.882, 0.960)
Lumbar spine BMC (g) 55.68 (51.72, 59.64) 56.22 (52.39, 60.04) 57.72 (52.67, 62.78) 58.87 (49.95, 61.42)
Lumbar spine area (cm2) 52.91 (50.18, 55.64) 51.56 (48.93, 54.19) 56.68 (53.08, 60.28) 53.66 (49.48, 57.85)
Lumbar spine BMD (g/cm2) 1.046 (1.003, 1.090) 1.085 (1.043, 1.127) 1.008 (0.957, 1.059) 1.041 (0.987, 1.095)
a p value for estimated mean baseline difference between EDS and CON < 0.05
b p value for estimated mean difference at V2 between EDS and CON < 0.05
c p value for estimated mean difference between V1 and V2 for EDS < 0.05
d p value for estimated mean difference between V1 and V2 for CON < 0.05
e p value for interaction time*group < 0.05
Values are the estimated means and 95% confidence interval. hEDS/HSD hypermobile EDS/hypermobility spectrum disorder; BMC bone mineral
content; BMD bone mineral density
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Table 3 shows pQCT-derived bone parameters. At baseline
and follow-up, a smaller cortical bone area, lower cortical
BMC, smaller cortical thickness, and lower SSIp was ob-
served in hEDS/HSD patients compared with the control sub-
jects (all p < 0.05). A statistical trend could be seen with lower
trabecular BMC in the hEDS/HSD subgroup (p = 0.063). In
contrast, no differences in trabecular or cortical vBMD, peri-
osteal circumference, endosteal circumference, endosteal/
periosteal circumference ratio, and trabecular bone area be-
tween hEDS/HSD and control groups were found (all
p > 0.05). Longitudinally, no significant changes in pQCT-
derived parameters were observed.
Discussion
This study investigated differences in anthropometry, overall
and regional body composition, bone geometry, and estimates
of bone strength between hEDS/HSD and control subjects in
cross-sectional and longitudinal analyses. Results show that
hEDS/HSD patients have similar trabecular and cortical
vBMD, but present with a cortical bone size deficit and a
lower bone strength index (SSIp) as compared with control
subjects. Thus although DXA-derived aBMD and Z-score did
not differ between hEDS/HSD patients and controls, their
smaller bone size might contribute to their increased fracture
risk. Indeed, prevalence of major fractures was significantly
higher in our hEDS/HSD patients, confirming current
literature [7–9, 11, 22–25]. The lower muscle CSA in combi-
nation with a normal BMR in the hEDS/HSD-group suggests
that their skeletal mechanosensitivity is not impaired and that
this bone size deficit might be secondary due to decreased
mechanical loading. It has been demonstrated in different co-
horts that these patients have lower physical activity levels and
muscle dysfunction mainly due to altered muscle tendon tis-
sue properties, fatigue, pain, and neuromuscular impairment
[26, 27]. In addition, we found no arguments for accelerated
bone loss or differential aging-related changes in bone or mus-
cle characteristics in hEDS/HSD patients as compared with
controls, except for a decline in muscle density in hEDS/
HSD which was not observed in the control group. Taken
together, our data suggest that the increased fracture risk in
hEDS/HSDmight be due to a lesser peak bone mass and bone
size attainment secondary to muscle disuse and lesser strain on
bone during growth and adolescence. However, the possibility
that there might be a genetic contribution to their increased
fracture risk cannot be excluded.
In addition, it has been shown that hEDS/HSD patients are
more prone to balance and gait impairments causing an in-
crease in fall frequency, which is considered as the primary
determinant for fractures [28]. As such, multi-facetted inter-
ventions focusing on physical activity, muscle strength, and
balance enhancement might be of benefit in this patient pop-
ulation. However, until now it is unclear what the optimal
physical rehabilitation program for hEDS/HSD patients
should be. It has been proposed that physiotherapy should
Table 3 pQCT bone-parameters at baseline and follow-up
Baseline Follow-up
hEDS/HSD-group (n = 39) Control group (n = 43) hEDS/HSD-group (n = 27) Control group (n = 17)
Trabecular BMC (mg/mm) 103.4 (97.5, 109.3) 111.5 (105.8, 117.2) 98.1 (91.2, 105.1) 107.6 (100.3, 115.0)
Trabecular bone area (mm2) 476.4 (461.7, 491.0) 491.7 (477.6, 505.8) d 464.9 (448.2, 481.7) 476.0 (458.9, 493.2)
Trabecular vBMD (mg/cm3) 219 (207, 231) 226 (214, 237) 215 (202, 229) 224 (211, 238)
Cortical BMC (mg/mm) 301.9 (287.5, 316.3) a 325.3 (311.8, 338.9) 300.7 (284.0, 317.5) b 327.4 (309.1, 345.7)
Cortical bone area (mm2) 271.8 (260.1, 283.5) a 290.7 (279.7, 301.7) 269.2 (255.9, 282.4) b 290.4 (276.6, 304.2)
Cortical vBMD (mg/cm3) 1110 (1097, 1122) 1117 (1106, 1129) 1116 (1100, 1132) 1123 (1103, 1142)
Cortical thickness (mm) 3.9 (3.7, 4.1) a 4.4 (4.2, 4.6) 3.7 (3.4, 4.0) b 4.2 (3.9, 4.7)
Periosteal circumference (mm) 88.3 (86.2, 90.4) 89.1 (87.1, 91.1) 86.6 (83.9, 89.2) 86.6 (83.3, 90.0)
Endosteal circumference (mm) 65.9 (63.2, 68.6) 65.4 (62.8, 67.9) 64.1 (60.6, 67.6) 62.1 (57.7, 66.5)
Endo/Peri circumference (%) 74.4 (72.9, 76.0) 73.1 (71.6, 74.6) 73.7 (71.7, 75.8) 71.4 (68.9, 74.0)
SSIp (mm3) 2121 (1865, 2377) a 2515 (2271, 2759) 2124 (1851, 2398) b 2521 (2253, 2788)
a p value for estimated mean baseline difference between EDS and CON < 0.05
b p value for estimated mean difference at V2 between EDS and CON < 0.05
c p value for estimated mean difference between V1 and V2 for EDS < 0.05
d p value for estimated mean difference between V1 and V2 for CON < 0.05
e p value for interaction time*group < 0.05
Values are the estimated means and 95% confidence interval. hEDS/HSD hypermobile EDS/hypermobility spectrum disorder; SSI strength strain index.
BMC bone mineral content; BMD bone mineral density
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focus on the symptomatic treatment of acute complaints to-
gether with exercise therapy to improve the joint motor con-
trol, proprioception, and muscle strength [27–30]. However,
the exact effects of physical therapy on the patients’ bone
phenotype need further research. According to the
mechanostat model, the effect of bone strength on mechanical
loading is proportional to the amount of strain experienced by
the bone tissue, which in turn depends on exercise type as well
as on load magnitude, direction, and duration. Exercise load-
ing should be dynamic, moderate-to-high intense, multidirec-
tional, non-repetitive, and short in duration for optimal en-
hancement of bone strength [31–35]. However, due to a re-
duced load capacity, and the variety and complexity of com-
plaints of patients with EDS and HSD, exercises should al-
ways be individually tailored and adapted, and executed with
prudence and patience.
Strengths of this study include the matched cross-sectional
analysis with longitudinal follow-up after 8 years in a relative-
ly large sample size for this disease entity. To the best of our
knowledge, this is the first follow-up study conducted in a
hEDS/HSD population and the first study that used pQCT.
The limitations of the study include the relatively low partic-
ipation rate of the control subjects at follow-up, and the fact
that hip DXA was not performed. Further, fracture data was
obtained by questionnaires and not from medical reports, and
no information on the circumstances of the fracture was avail-
able. In addition, selection of the patients could not rely on the
2017 hEDS/HSD diagnostic criteria as baselinemeasurements
were performed in 2009. However, all patients who participat-
ed in the follow-up were re-evaluated and re-labeled accord-
ing to the 2017 criteria, and statistical analyses could not re-
veal any differences in bone characteristics between hEDS
and HSD participants.
Conclusion
In this population of women with hEDS/HSD, we confirmed a
higher fracture prevalence and similar aBMD. In addition,
cortical and cross-sectional muscle area, without differences
in indices of bone’s mechanosensitivity or vBMD, suggest
that hEDS/HSD patients likely present with a bone size deficit
secondary due to lower mechanical strain. It remains to be
investigated whether engaging in physical rehabilitation pro-
grams will affect their skeletal phenotype and fracture risk.
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